# A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer

> **NCT03300921** · PHASE1 · TERMINATED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 3 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Paricalcitol

## Key facts

- **NCT ID:** NCT03300921
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-09-28
- **Primary completion:** 2020-08-30
- **Final completion:** 2022-03-23
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Newer research suggested that paricalcitol may be harmful to a subset of pancreatic cancer patients and it is not feasible to subtype patients in the short time frame before surgery
- **Last updated:** 2022-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03300921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03300921, "A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03300921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*